TrialJournal of clinical pharmacology2025
Population Pharmacokinetics and Exposure-Response Relationships of Etrolizumab in Patients with Moderately-to-Severely Active Crohn's Disease.
Anita Moein et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.